Vir Biotechnology, Inc. (NASDAQ:VIR) Receives $21.57 Consensus Price Target from Brokerages

Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) have received an average rating of “Moderate Buy” from the eight ratings firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $21.5714.

Several brokerages have commented on VIR. Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Wednesday, July 8th. Leerink Partners increased their price objective on Vir Biotechnology from $20.00 to $21.00 and gave the stock an “outperform” rating in a report on Wednesday, June 3rd. HC Wainwright restated a “buy” rating on shares of Vir Biotechnology in a research report on Monday, August 10th. Morgan Stanley set a $25.00 target price on Vir Biotechnology in a research note on Thursday, August 6th. Finally, Wall Street Zen upgraded Vir Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th.

Vir Biotechnology Price Performance

Shares of NASDAQ VIR opened at $10.62 on Friday. The firm has a market capitalization of $1.80 billion, a PE ratio of -5.71 and a beta of 1.63. Vir Biotechnology has a 1-year low of $4.75 and a 1-year high of $11.94. The business’s fifty day moving average price is $9.83 and its two-hundred day moving average price is $9.55.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.33 by $0.14. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 29.99%. The company had revenue of $238.95 million during the quarter, compared to the consensus estimate of $135.88 million. During the same quarter in the previous year, the company posted ($0.80) earnings per share. The company’s revenue for the quarter was up 19582.5% compared to the same quarter last year. Equities research analysts expect that Vir Biotechnology will post -1.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of VIR. Fiduciary Financial Advisors acquired a new position in shares of Vir Biotechnology in the 2nd quarter worth approximately $29,000. Raymond James Financial Inc. acquired a new stake in shares of Vir Biotechnology during the 2nd quarter valued at $35,000. UMB Bank n.a. lifted its position in shares of Vir Biotechnology by 1,418.7% during the 4th quarter. UMB Bank n.a. now owns 7,062 shares of the company’s stock valued at $43,000 after acquiring an additional 6,597 shares during the last quarter. CWM LLC grew its holdings in shares of Vir Biotechnology by 23.0% in the 4th quarter. CWM LLC now owns 8,804 shares of the company’s stock worth $53,000 after acquiring an additional 1,646 shares during the last quarter. Finally, Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Vir Biotechnology in the 4th quarter worth $60,000. 65.32% of the stock is owned by institutional investors and hedge funds.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.